EPISODE · Mar 2, 2026 · 5 MIN
Unapproved Therapies, Henrietta Lacks Settlement, and At-Home Ketamine: Key Healthcare Updates
from NextGen Patient Voice · host Peter Loupos
Welcome to today's episode, where we delve into the latest developments in the healthcare landscape. First, we explore "Principles for Access to Unapproved Therapies," a document from rarediseases.org that outlines guidelines for accessing unapproved medical treatments for rare diseases. It emphasizes ethical considerations, patient safety, and the need for transparent communication among patients, healthcare providers, and regulatory bodies. The document advocates for equitable access and a collaborative approach to developing and distributing these therapies. Next, we discuss the promise of novel therapies for rare diseases. These innovative treatments aim to address unmet medical needs and reduce long-term healthcare costs. However, challenges like high development costs and accessibility issues persist, highlighting the need for continued investment and policy support. In genetics research, scientists are examining ancient human defenses to develop new therapies. By understanding genetic variations that evolved to protect against ancient pathogens, researchers aim to create targeted treatments for modern diseases, potentially leading to innovative therapies that harness the body's natural defenses. Meanwhile, Stat News reports a settlement between the estate of Henrietta Lacks and Novartis over the use of HeLa cells, marking a significant moment in discussions about ethics and consent in medical research. In other news, Centene urges CMS to reduce bureaucratic hurdles in Medicaid fraud prevention, while former UVA Health CEO Dr. K. Craig Kent files a defamation lawsuit. Blue Cross Michigan reports reduced losses, and CMS plans to halt new enrollments for Elevance Health's Medicare Advantage program. Finally, Michael Alvear's analysis of Reddit discussions on at-home ketamine therapy reveals concerning trends of self-administration without medical supervision, raising safety concerns and highlighting the need for better regulation and oversight. Stay tuned for more updates and insights in our next episode. https://www.lucidhealthsolutions.com https://www.lucidhealthsolutions.com 📚 Sources: https://rarediseases.org/wp-content/uploads/2017/05/CommunityExpandedAccessPrinciples_May2Final.pdf https://everylifefoundation.org/wp-content/uploads/2017/09/Chris-Austin-NIH.pdf https://www.nejm.org/doi/abs/10.1056/NEJMe078017 https://www.statnews.com/2026/02/28/henrietta-lacks-novartis-settlement-over-hela-cell-line/ https://www.modernhealthcare.com/insurance/mh-centene-cms-medicaid-fraud-crackdown/ https://www.statnews.com/2026/02/27/rare-diseases-plausible-mechanism-pathway-fda/
What this episode covers
Welcome to today's episode, where we delve into the latest developments in the healthcare landscape. First, we explore "Principles for Access to Unapproved Therapies," a document from rarediseases.org that outlines guidelines for accessing unapproved medical treatments for rare diseases. It emphasizes ethical considerations, patient safety, and the need for transparent communication among patients, healthcare providers, and regulatory bodies. The document advocates for equitable access and a collaborative approach to developing and distributing these therapies. Next, we discuss the promise of novel therapies for rare diseases. These innovative treatments aim to address unmet medical needs and reduce long-term healthcare costs. However, challenges like high development costs and accessibility issues persist, highlighting the need for continued investment and policy support. In genetics research, scientists are examining ancient human defenses to develop new therapies. By understanding genetic variations that evolved to protect against ancient pathogens, researchers aim to create targeted treatments for modern diseases, potentially leading to innovative therapies that harness the body's natural defenses. Meanwhile, Stat News reports a settlement between the estate of Henrietta Lacks and Novartis over the use of HeLa cells, marking a significant moment in discussions about ethics and consent in medical research. In other news, Centene urges CMS to reduce bureaucratic hurdles in Medicaid fraud prevention, while former UVA Health CEO Dr. K. Craig Kent files a defamation lawsuit. Blue Cross Michigan reports reduced losses, and CMS plans to halt new enrollments for Elevance Health's Medicare Advantage program. Finally, Michael Alvear's analysis of Reddit discussions on at-home ketamine therapy reveals concerning trends of self-administration without medical supervision, raising safety concerns and highlighting the need for better regulation and oversight. Stay tuned for more updates and insights in our next episode. https://www.lucidhealthsolutions.com https://www.lucidhealthsolutions.com 📚 Sources: https://rarediseases.org/wp-content/uploads/2017/05/CommunityExpandedAccessPrinciples_May2Final.pdf https://everylifefoundation.org/wp-content/uploads/2017/09/Chris-Austin-NIH.pdf https://www.nejm.org/doi/abs/10.1056/NEJMe078017 https://www.statnews.com/2026/02/28/henrietta-lacks-novartis-settlement-over-hela-cell-line/ https://www.modernhealthcare.com/insurance/mh-centene-cms-medicaid-fraud-crackdown/ https://www.statnews.com/2026/02/27/rare-diseases-plausible-mechanism-pathway-fda/
NOW PLAYING
Unapproved Therapies, Henrietta Lacks Settlement, and At-Home Ketamine: Key Healthcare Updates
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.